ID   NMNA1_HUMAN             Reviewed;         279 AA.
AC   Q9HAN9; B1AN63; Q8TAE9; Q9H247; Q9H6B6;
DT   09-MAY-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   15-MAR-2017, entry version 146.
DE   RecName: Full=Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 {ECO:0000305};
DE            Short=NMN/NaMN adenylyltransferase 1;
DE            EC=2.7.7.1;
DE            EC=2.7.7.18;
DE   AltName: Full=Nicotinamide-nucleotide adenylyltransferase 1;
DE            Short=NMN adenylyltransferase 1;
DE   AltName: Full=Nicotinate-nucleotide adenylyltransferase 1;
DE            Short=NaMN adenylyltransferase 1;
GN   Name=NMNAT1; Synonyms=NMNAT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:AAG33632.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 208-225 AND 262-272,
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH ADPRT.
RX   PubMed=11248244; DOI=10.1016/S0014-5793(01)02180-9;
RA   Schweiger M., Hennig K., Lerner F., Niere M., Hirsch-Kauffmann M.,
RA   Specht T., Weise C., Oei S.L., Ziegler M.;
RT   "Characterization of recombinant human nicotinamide mononucleotide
RT   adenylyl transferase (NMNAT), a nuclear enzyme essential for NAD
RT   synthesis.";
RL   FEBS Lett. 492:95-100(2001).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 238-250 AND 262-272,
RP   COFACTOR, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=11027696; DOI=10.1074/jbc.M008700200;
RA   Emanuelli M., Carnevali F., Saccucci F., Pierella F., Amici A.,
RA   Raffaelli N., Magni G.;
RT   "Molecular cloning, chromosomal localization, tissue mRNA levels,
RT   bacterial expression, and enzymatic properties of human NMN
RT   adenylyltransferase.";
RL   J. Biol. Chem. 276:406-412(2001).
RN   [3] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=11891043; DOI=10.1016/S0378-1119(02)00394-3;
RA   Fernando F.S., Conforti L., Tosi S., Smith A.D., Coleman M.P.;
RT   "Human homologue of a gene mutated in the slow Wallerian degeneration
RT   (C57BL/Wld(s)) mouse.";
RL   Gene 284:23-29(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6] {ECO:0000312|EMBL:BAB15345.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12574164; DOI=10.1074/jbc.M300073200;
RA   Zhang X., Kurnasov O.V., Karthikeyan S., Grishin N.V., Osterman A.L.,
RA   Zhang H.;
RT   "Structural characterization of a human cytosolic NMN/NaMN
RT   adenylyltransferase and implication in human NAD biosynthesis.";
RL   J. Biol. Chem. 278:13503-13511(2003).
RN   [9]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR LOCATION.
RX   PubMed=16118205; DOI=10.1074/jbc.M508660200;
RA   Berger F., Lau C., Dahlmann M., Ziegler M.;
RT   "Subcellular compartmentation and differential catalytic properties of
RT   the three human nicotinamide mononucleotide adenylyltransferase
RT   isoforms.";
RL   J. Biol. Chem. 280:36334-36341(2005).
RN   [10]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND
RP   COFACTOR.
RX   PubMed=17402747; DOI=10.1021/bi6023379;
RA   Sorci L., Cimadamore F., Scotti S., Petrelli R., Cappellacci L.,
RA   Franchetti P., Orsomando G., Magni G.;
RT   "Initial-rate kinetics of human NMN-adenylyltransferases: substrate
RT   and metal ion specificity, inhibition by products and multisubstrate
RT   analogues, and isozyme contributions to NAD+ biosynthesis.";
RL   Biochemistry 46:4912-4922(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   SUBCELLULAR LOCATION, VARIANTS LCA9 THR-13; PHE-67; GLY-98; PHE-151;
RP   TRP-207; LEU-237; LYS-257 AND ASP-273, AND CHARACTERIZATION OF
RP   VARIANTS LCA9 TRP-207; LYS-257 AND ASP-273.
RX   PubMed=22842230; DOI=10.1038/ng.2356;
RA   Koenekoop R.K., Wang H., Majewski J., Wang X., Lopez I., Ren H.,
RA   Chen Y., Li Y., Fishman G.A., Genead M., Schwartzentruber J.,
RA   Solanki N., Traboulsi E.I., Cheng J., Logan C.V., McKibbin M.,
RA   Hayward B.E., Parry D.A., Johnson C.A., Nageeb M., Poulter J.A.,
RA   Mohamed M.D., Jafri H., Rashid Y., Taylor G.R., Keser V., Mardon G.,
RA   Xu H., Inglehearn C.F., Fu Q., Toomes C., Chen R.;
RT   "Mutations in NMNAT1 cause Leber congenital amaurosis and identify a
RT   new disease pathway for retinal degeneration.";
RL   Nat. Genet. 44:1035-1039(2012).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-117, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-117 AND THR-119, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   FUNCTION.
RX   PubMed=27257257; DOI=10.1126/science.aad9335;
RA   Wright R.H., Lioutas A., Le Dily F., Soronellas D., Pohl A., Bonet J.,
RA   Nacht A.S., Samino S., Font-Mateu J., Vicent G.P., Wierer M.,
RA   Trabado M.A., Schelhorn C., Carolis C., Macias M.J., Yanes O.,
RA   Oliva B., Beato M.;
RT   "ADP-ribose-derived nuclear ATP synthesis by NUDIX5 is required for
RT   chromatin remodeling.";
RL   Science 352:1221-1225(2016).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 5-278 IN COMPLEX WITH
RP   SUBSTRATE NMN.
RX   PubMed=11959140; DOI=10.1016/S0014-5793(02)02556-5;
RA   Werner E., Ziegler M., Lerner F., Schweiger M., Heinemann U.;
RT   "Crystal structure of human nicotinamide mononucleotide
RT   adenylyltransferase in complex with NMN.";
RL   FEBS Lett. 516:239-244(2002).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   PubMed=11751893; DOI=10.1074/jbc.M111589200;
RA   Garavaglia S., D'Angelo I., Emanuelli M., Carnevali F., Pierella F.,
RA   Magni G., Rizzi M.;
RT   "Structure of human NMN adenylyltransferase. A key nuclear enzyme for
RT   NAD homeostasis.";
RL   J. Biol. Chem. 277:8524-8530(2002).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH PRODUCTS NAD AND
RP   NAAD.
RX   PubMed=11788603; DOI=10.1074/jbc.M111469200;
RA   Zhou T., Kurnasov O., Tomchick D.R., Binns D.D., Grishin N.V.,
RA   Marquez V.E., Osterman A.L., Zhang H.;
RT   "Structure of human nicotinamide/nicotinic acid mononucleotide
RT   adenylyltransferase. Basis for the dual substrate specificity and
RT   activation of the oncolytic agent tiazofurin.";
RL   J. Biol. Chem. 277:13148-13154(2002).
RN   [19]
RP   VARIANTS LCA9 THR-35; GLY-98; PHE-151; VAL-153; LYS-257 AND ASP-273.
RX   PubMed=22842231; DOI=10.1038/ng.2370;
RA   Chiang P.W., Wang J., Chen Y., Fu Q., Zhong J., Chen Y., Yi X., Wu R.,
RA   Gan H., Shi Y., Chen Y., Barnett C., Wheaton D., Day M.,
RA   Sutherland J., Heon E., Weleber R.G., Gabriel L.A., Cong P.,
RA   Chuang K., Ye S., Sallum J.M., Qi M.;
RT   "Exome sequencing identifies NMNAT1 mutations as a cause of Leber
RT   congenital amaurosis.";
RL   Nat. Genet. 44:972-974(2012).
RN   [20]
RP   VARIANTS LCA9 THR-13; VAL-69; PRO-147; PRO-153; GLY-173; MET-178;
RP   CYS-181; TRP-207; ASN-217; CYS-237; SER-239 AND PRO-251.
RX   PubMed=22842229; DOI=10.1038/ng.2357;
RA   Perrault I., Hanein S., Zanlonghi X., Serre V., Nicouleau M.,
RA   Defoort-Delhemmes S., Delphin N., Fares-Taie L., Gerber S., Xerri O.,
RA   Edelson C., Goldenberg A., Duncombe A., Le Meur G., Hamel C.,
RA   Silva E., Nitschke P., Calvas P., Munnich A., Roche O., Dollfus H.,
RA   Kaplan J., Rozet J.M.;
RT   "Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset
RT   severe macular and optic atrophy.";
RL   Nat. Genet. 44:975-977(2012).
RN   [21]
RP   VARIANTS LCA9 MET-9; THR-13; ASN-20; GLY-33; VAL-54; TRP-66; VAL-69;
RP   HIS-72; GLY-98; ARG-156; MET-184; CYS-237 AND LYS-257, AND
RP   CHARACTERIZATION OF VARIANTS LCA9 MET-9; TRP-66 AND CYS-237.
RX   PubMed=22842227; DOI=10.1038/ng.2361;
RA   Falk M.J., Zhang Q., Nakamaru-Ogiso E., Kannabiran C.,
RA   Fonseca-Kelly Z., Chakarova C., Audo I., Mackay D.S., Zeitz C.,
RA   Borman A.D., Staniszewska M., Shukla R., Palavalli L., Mohand-Said S.,
RA   Waseem N.H., Jalali S., Perin J.C., Place E., Ostrovsky J., Xiao R.,
RA   Bhattacharya S.S., Consugar M., Webster A.R., Sahel J.A., Moore A.T.,
RA   Berson E.L., Liu Q., Gai X., Pierce E.A.;
RT   "NMNAT1 mutations cause Leber congenital amaurosis.";
RL   Nat. Genet. 44:1040-1045(2012).
CC   -!- FUNCTION: Catalyzes the formation of NAD(+) from nicotinamide
CC       mononucleotide (NMN) and ATP (PubMed:17402747). Can also use the
CC       deamidated form; nicotinic acid mononucleotide (NaMN) as substrate
CC       with the same efficiency (PubMed:17402747). Can use triazofurin
CC       monophosphate (TrMP) as substrate (PubMed:17402747). Also
CC       catalyzes the reverse reaction, i.e. the pyrophosphorolytic
CC       cleavage of NAD(+) (PubMed:17402747). For the pyrophosphorolytic
CC       activity, prefers NAD(+) and NaAD as substrates and degrades NADH,
CC       nicotinic acid adenine dinucleotide phosphate (NHD) and
CC       nicotinamide guanine dinucleotide (NGD) less effectively
CC       (PubMed:17402747). Involved in the synthesis of ATP in the
CC       nucleus, together with PARP1, PARG and NUDT5 (PubMed:27257257).
CC       Nuclear ATP generation is required for extensive chromatin
CC       remodeling events that are energy-consuming (PubMed:27257257).
CC       Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and
CC       NaADP(+) (PubMed:17402747). Protects against axonal degeneration
CC       following mechanical or toxic insults (By similarity).
CC       {ECO:0000250|UniProtKB:Q9EPA7, ECO:0000269|PubMed:17402747,
CC       ECO:0000269|PubMed:27257257}.
CC   -!- CATALYTIC ACTIVITY: ATP + nicotinamide ribonucleotide =
CC       diphosphate + NAD(+). {ECO:0000269|PubMed:11027696}.
CC   -!- CATALYTIC ACTIVITY: ATP + beta-nicotinate-D-ribonucleotide =
CC       diphosphate + deamido-NAD(+).
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:11027696,
CC         ECO:0000269|PubMed:17402747};
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11027696,
CC         ECO:0000269|PubMed:17402747};
CC       Note=Divalent metal cations. Zn(2+) confers higher activity as
CC       compared to Mg(2+). {ECO:0000269|PubMed:11027696,
CC       ECO:0000269|PubMed:17402747};
CC   -!- ENZYME REGULATION: Activity is strongly inhibited by galotannin.
CC       Inhibited by P1-(adenosine-5')-P4-(nicotinic-acid-riboside-5')-
CC       tetraphosphate (Nap4AD). {ECO:0000269|PubMed:17402747}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=34 uM for NMN {ECO:0000269|PubMed:16118205,
CC         ECO:0000269|PubMed:17402747};
CC         KM=40 uM for ATP {ECO:0000269|PubMed:16118205,
CC         ECO:0000269|PubMed:17402747};
CC         KM=937 uM for PPi {ECO:0000269|PubMed:16118205,
CC         ECO:0000269|PubMed:17402747};
CC         KM=59 uM for NAD(+) {ECO:0000269|PubMed:16118205,
CC         ECO:0000269|PubMed:17402747};
CC         Vmax=25 umol/min/mg enzyme for NAD synthesis
CC         {ECO:0000269|PubMed:16118205, ECO:0000269|PubMed:17402747};
CC         Vmax=60.5 umol/min/ug enzyme for NAD(+) cleavage
CC         {ECO:0000269|PubMed:16118205, ECO:0000269|PubMed:17402747};
CC         Vmax=8.5 umol/min/ug enzyme for NADH cleavage
CC         {ECO:0000269|PubMed:16118205, ECO:0000269|PubMed:17402747};
CC   -!- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from
CC       nicotinamide D-ribonucleotide: step 1/1.
CC   -!- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; deamido-
CC       NAD(+) from nicotinate D-ribonucleotide: step 1/1.
CC   -!- SUBUNIT: Homohexamer. Interacts with ADPRT/PARP1.
CC       {ECO:0000269|PubMed:11248244, ECO:0000269|PubMed:11751893}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-3917542, EBI-3917542;
CC       P24863:CCNC; NbExp=3; IntAct=EBI-3917542, EBI-395261;
CC       Q6NVW7:KPNA2; NbExp=3; IntAct=EBI-3917542, EBI-9377406;
CC       Q96EB6:SIRT1; NbExp=3; IntAct=EBI-3917542, EBI-1802965;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11248244,
CC       ECO:0000269|PubMed:12574164, ECO:0000269|PubMed:16118205,
CC       ECO:0000269|PubMed:22842230}.
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels in
CC       skeletal muscle, heart and kidney. Also expressed in the liver
CC       pancreas and placenta. Widely expressed throughout the brain.
CC       {ECO:0000269|PubMed:11027696, ECO:0000269|PubMed:11891043}.
CC   -!- DISEASE: Leber congenital amaurosis 9 (LCA9) [MIM:608553]: A
CC       severe dystrophy of the retina, typically becoming evident in the
CC       first years of life. Visual function is usually poor and often
CC       accompanied by nystagmus, sluggish or near-absent pupillary
CC       responses, photophobia, high hyperopia and keratoconus.
CC       {ECO:0000269|PubMed:22842227, ECO:0000269|PubMed:22842229,
CC       ECO:0000269|PubMed:22842230, ECO:0000269|PubMed:22842231}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the eukaryotic NMN adenylyltransferase
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF314163; AAG33632.1; -; mRNA.
DR   EMBL; AF312734; AAG33629.1; -; mRNA.
DR   EMBL; AF459819; AAL76934.1; -; mRNA.
DR   EMBL; AF459823; AAL76935.1; -; Genomic_DNA.
DR   EMBL; AF459820; AAL76935.1; JOINED; Genomic_DNA.
DR   EMBL; AF459821; AAL76935.1; JOINED; Genomic_DNA.
DR   EMBL; AF459822; AAL76935.1; JOINED; Genomic_DNA.
DR   EMBL; AK026065; BAB15345.1; -; mRNA.
DR   EMBL; AK315640; BAG38007.1; -; mRNA.
DR   EMBL; AL603962; CAI16813.1; -; Genomic_DNA.
DR   EMBL; AL357140; CAI16813.1; JOINED; Genomic_DNA.
DR   EMBL; AL357140; CAI16889.1; -; Genomic_DNA.
DR   EMBL; AL603962; CAI16889.1; JOINED; Genomic_DNA.
DR   EMBL; CH471130; EAW71635.1; -; Genomic_DNA.
DR   EMBL; BC014943; AAH14943.1; -; mRNA.
DR   CCDS; CCDS108.1; -.
DR   RefSeq; NP_001284707.1; NM_001297778.1.
DR   RefSeq; NP_073624.2; NM_022787.3.
DR   RefSeq; XP_016857596.1; XM_017002107.1.
DR   UniGene; Hs.633762; -.
DR   PDB; 1GZU; X-ray; 2.90 A; A/B/C=2-279.
DR   PDB; 1KKU; X-ray; 2.50 A; A=1-279.
DR   PDB; 1KQN; X-ray; 2.20 A; A/B/C/D/E/F=1-279.
DR   PDB; 1KQO; X-ray; 2.50 A; A/B/C/D/E/F=1-279.
DR   PDB; 1KR2; X-ray; 2.30 A; A/B/C/D/E/F=1-279.
DR   PDBsum; 1GZU; -.
DR   PDBsum; 1KKU; -.
DR   PDBsum; 1KQN; -.
DR   PDBsum; 1KQO; -.
DR   PDBsum; 1KR2; -.
DR   ProteinModelPortal; Q9HAN9; -.
DR   SMR; Q9HAN9; -.
DR   BioGrid; 122308; 39.
DR   DIP; DIP-60881N; -.
DR   IntAct; Q9HAN9; 19.
DR   STRING; 9606.ENSP00000366410; -.
DR   DrugBank; DB04099; Deamido-Nad+.
DR   DrugBank; DB03227; Nicotinamide Mononucleotide.
DR   iPTMnet; Q9HAN9; -.
DR   PhosphoSitePlus; Q9HAN9; -.
DR   BioMuta; NMNAT1; -.
DR   DMDM; 30580491; -.
DR   EPD; Q9HAN9; -.
DR   MaxQB; Q9HAN9; -.
DR   PaxDb; Q9HAN9; -.
DR   PeptideAtlas; Q9HAN9; -.
DR   PRIDE; Q9HAN9; -.
DR   DNASU; 64802; -.
DR   Ensembl; ENST00000377205; ENSP00000366410; ENSG00000173614.
DR   Ensembl; ENST00000462686; ENSP00000435134; ENSG00000173614.
DR   GeneID; 64802; -.
DR   KEGG; hsa:64802; -.
DR   UCSC; uc001aqp.3; human.
DR   CTD; 64802; -.
DR   DisGeNET; 64802; -.
DR   GeneCards; NMNAT1; -.
DR   GeneReviews; NMNAT1; -.
DR   HGNC; HGNC:17877; NMNAT1.
DR   HPA; HPA059447; -.
DR   MalaCards; NMNAT1; -.
DR   MIM; 608553; phenotype.
DR   MIM; 608700; gene.
DR   neXtProt; NX_Q9HAN9; -.
DR   OpenTargets; ENSG00000173614; -.
DR   Orphanet; 65; Leber congenital amaurosis.
DR   PharmGKB; PA31660; -.
DR   eggNOG; KOG3199; Eukaryota.
DR   eggNOG; COG1057; LUCA.
DR   GeneTree; ENSGT00530000063189; -.
DR   HOGENOM; HOG000216047; -.
DR   HOVERGEN; HBG052640; -.
DR   InParanoid; Q9HAN9; -.
DR   KO; K06210; -.
DR   OMA; RVAMCQL; -.
DR   OrthoDB; EOG091G0JTI; -.
DR   PhylomeDB; Q9HAN9; -.
DR   TreeFam; TF315035; -.
DR   BioCyc; MetaCyc:HS10701-MONOMER; -.
DR   BRENDA; 2.7.7.1; 2681.
DR   BRENDA; 2.7.7.18; 2681.
DR   Reactome; R-HSA-196807; Nicotinate metabolism.
DR   SABIO-RK; Q9HAN9; -.
DR   UniPathway; UPA00253; UER00332.
DR   UniPathway; UPA00253; UER00600.
DR   ChiTaRS; NMNAT1; human.
DR   EvolutionaryTrace; Q9HAN9; -.
DR   GeneWiki; NMNAT1; -.
DR   GenomeRNAi; 64802; -.
DR   PRO; PR:Q9HAN9; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000173614; -.
DR   CleanEx; HS_NMNAT1; -.
DR   ExpressionAtlas; Q9HAN9; baseline and differential.
DR   Genevisible; Q9HAN9; HS.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000309; F:nicotinamide-nucleotide adenylyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0004515; F:nicotinate-nucleotide adenylyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0034628; P:'de novo' NAD biosynthetic process from aspartate; IBA:GO_Central.
DR   GO; GO:1990966; P:ATP generation from poly-ADP-D-ribose; IDA:UniProtKB.
DR   GO; GO:0009435; P:NAD biosynthetic process; IC:UniProtKB.
DR   GO; GO:0019674; P:NAD metabolic process; TAS:Reactome.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   Gene3D; 3.40.50.620; -; 1.
DR   InterPro; IPR004821; Cyt_trans-like.
DR   InterPro; IPR005248; NadD/NMNAT.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   Pfam; PF01467; CTP_transf_like; 1.
DR   TIGRFAMs; TIGR00482; TIGR00482; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome;
KW   Direct protein sequencing; Disease mutation;
KW   Leber congenital amaurosis; Magnesium; NAD; Nucleotide-binding;
KW   Nucleotidyltransferase; Nucleus; Phosphoprotein;
KW   Pyridine nucleotide biosynthesis; Reference proteome; Transferase;
KW   Zinc.
FT   CHAIN         1    279       Nicotinamide/nicotinic acid
FT                                mononucleotide adenylyltransferase 1.
FT                                /FTId=PRO_0000135012.
FT   NP_BIND      15     17       ATP. {ECO:0000250|UniProtKB:Q96T66,
FT                                ECO:0000305|PubMed:11788603}.
FT   NP_BIND     156    158       ATP. {ECO:0000250|UniProtKB:Q96T66}.
FT   NP_BIND     224    227       ATP. {ECO:0000250|UniProtKB:Q96T66}.
FT   REGION       55     57       Substrate binding.
FT                                {ECO:0000269|PubMed:11959140}.
FT   REGION       92     95       Substrate binding.
FT                                {ECO:0000269|PubMed:11788603,
FT                                ECO:0000269|PubMed:11959140}.
FT   REGION      168    169       Substrate binding.
FT                                {ECO:0000269|PubMed:11788603,
FT                                ECO:0000269|PubMed:11959140}.
FT   MOTIF       123    129       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   BINDING      24     24       ATP. {ECO:0000250|UniProtKB:Q96T66}.
FT   BINDING      58     58       ATP. {ECO:0000250|UniProtKB:Q96T66}.
FT   MOD_RES     117    117       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     119    119       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VARIANT       9      9       V -> M (in LCA9; does not affect nuclear
FT                                localization; results in significantly
FT                                reduced enzymatic activity;
FT                                dbSNP:rs387907294).
FT                                {ECO:0000269|PubMed:22842227}.
FT                                /FTId=VAR_068856.
FT   VARIANT      13     13       A -> T (in LCA9; dbSNP:rs138613460).
FT                                {ECO:0000269|PubMed:22842227,
FT                                ECO:0000269|PubMed:22842229,
FT                                ECO:0000269|PubMed:22842230}.
FT                                /FTId=VAR_068857.
FT   VARIANT      20     20       I -> N (in LCA9; dbSNP:rs761948762).
FT                                {ECO:0000269|PubMed:22842227}.
FT                                /FTId=VAR_068858.
FT   VARIANT      33     33       D -> G (in LCA9).
FT                                {ECO:0000269|PubMed:22842227}.
FT                                /FTId=VAR_068859.
FT   VARIANT      35     35       M -> T (in LCA9).
FT                                {ECO:0000269|PubMed:22842231}.
FT                                /FTId=VAR_068860.
FT   VARIANT      54     54       A -> V (in LCA9; dbSNP:rs760965874).
FT                                {ECO:0000269|PubMed:22842227}.
FT                                /FTId=VAR_068861.
FT   VARIANT      66     66       R -> W (in LCA9; does not affect nuclear
FT                                localization; results in significantly
FT                                reduced enzymatic activity;
FT                                dbSNP:rs763325435).
FT                                {ECO:0000269|PubMed:22842227}.
FT                                /FTId=VAR_068862.
FT   VARIANT      67     67       V -> F (in LCA9; dbSNP:rs756903689).
FT                                {ECO:0000269|PubMed:22842230}.
FT                                /FTId=VAR_068863.
FT   VARIANT      69     69       M -> V (in LCA9; dbSNP:rs372066126).
FT                                {ECO:0000269|PubMed:22842227,
FT                                ECO:0000269|PubMed:22842229}.
FT                                /FTId=VAR_068864.
FT   VARIANT      72     72       L -> H (in LCA9).
FT                                {ECO:0000269|PubMed:22842227}.
FT                                /FTId=VAR_068865.
FT   VARIANT      98     98       V -> G (in LCA9; dbSNP:rs771336246).
FT                                {ECO:0000269|PubMed:22842227,
FT                                ECO:0000269|PubMed:22842230,
FT                                ECO:0000269|PubMed:22842231}.
FT                                /FTId=VAR_068866.
FT   VARIANT     147    147       A -> P (in LCA9).
FT                                {ECO:0000269|PubMed:22842229}.
FT                                /FTId=VAR_068867.
FT   VARIANT     151    151       V -> F (in LCA9; dbSNP:rs387907292).
FT                                {ECO:0000269|PubMed:22842230,
FT                                ECO:0000269|PubMed:22842231}.
FT                                /FTId=VAR_068868.
FT   VARIANT     153    153       L -> P (in LCA9).
FT                                {ECO:0000269|PubMed:22842229}.
FT                                /FTId=VAR_068869.
FT   VARIANT     153    153       L -> V (in LCA9; dbSNP:rs387907293).
FT                                {ECO:0000269|PubMed:22842231}.
FT                                /FTId=VAR_068870.
FT   VARIANT     156    156       G -> R (in LCA9).
FT                                {ECO:0000269|PubMed:22842227}.
FT                                /FTId=VAR_068871.
FT   VARIANT     173    173       D -> G (in LCA9).
FT                                {ECO:0000269|PubMed:22842229}.
FT                                /FTId=VAR_068872.
FT   VARIANT     178    178       V -> M (in LCA9; dbSNP:rs757724544).
FT                                {ECO:0000269|PubMed:22842229}.
FT                                /FTId=VAR_068873.
FT   VARIANT     181    181       Y -> C (in LCA9; dbSNP:rs748913297).
FT                                {ECO:0000269|PubMed:22842229}.
FT                                /FTId=VAR_068874.
FT   VARIANT     184    184       I -> M (in LCA9).
FT                                {ECO:0000269|PubMed:22842227}.
FT                                /FTId=VAR_068875.
FT   VARIANT     207    207       R -> W (in LCA9; results in significantly
FT                                reduced enzymatic activity;
FT                                dbSNP:rs142968179).
FT                                {ECO:0000269|PubMed:22842229,
FT                                ECO:0000269|PubMed:22842230}.
FT                                /FTId=VAR_068876.
FT   VARIANT     217    217       I -> N (in LCA9).
FT                                {ECO:0000269|PubMed:22842229}.
FT                                /FTId=VAR_068877.
FT   VARIANT     237    237       R -> C (in LCA9; does not affect nuclear
FT                                localization; dbSNP:rs375110174).
FT                                {ECO:0000269|PubMed:22842227,
FT                                ECO:0000269|PubMed:22842229}.
FT                                /FTId=VAR_068878.
FT   VARIANT     237    237       R -> L (in LCA9; dbSNP:rs368062092).
FT                                {ECO:0000269|PubMed:22842230}.
FT                                /FTId=VAR_068879.
FT   VARIANT     239    239       L -> S (in LCA9; dbSNP:rs778606847).
FT                                {ECO:0000269|PubMed:22842229}.
FT                                /FTId=VAR_068880.
FT   VARIANT     251    251       H -> P (in LCA9).
FT                                {ECO:0000269|PubMed:22842229}.
FT                                /FTId=VAR_068881.
FT   VARIANT     257    257       E -> K (in LCA9; results in significantly
FT                                reduced enzymatic activity; the mutant
FT                                localizes to the cytoplasm;
FT                                dbSNP:rs150726175).
FT                                {ECO:0000269|PubMed:22842227,
FT                                ECO:0000269|PubMed:22842230,
FT                                ECO:0000269|PubMed:22842231}.
FT                                /FTId=VAR_068882.
FT   VARIANT     273    273       N -> D (in LCA9; results in significantly
FT                                reduced enzymatic activity;
FT                                dbSNP:rs387907291).
FT                                {ECO:0000269|PubMed:22842230,
FT                                ECO:0000269|PubMed:22842231}.
FT                                /FTId=VAR_068883.
FT   CONFLICT     20     20       I -> F (in Ref. 2; AAL76934/AAL76935).
FT                                {ECO:0000305}.
FT   CONFLICT    217    217       I -> F (in Ref. 3; AAG33629).
FT                                {ECO:0000305}.
FT   STRAND        7     15       {ECO:0000244|PDB:1KQN}.
FT   HELIX        22     37       {ECO:0000244|PDB:1KQN}.
FT   STRAND       39     50       {ECO:0000244|PDB:1KQN}.
FT   HELIX        53     55       {ECO:0000244|PDB:1KQN}.
FT   HELIX        63     73       {ECO:0000244|PDB:1KQN}.
FT   TURN         74     76       {ECO:0000244|PDB:1KQN}.
FT   STRAND       78     82       {ECO:0000244|PDB:1KQN}.
FT   HELIX        86     88       {ECO:0000244|PDB:1KQN}.
FT   HELIX        95    106       {ECO:0000244|PDB:1KQN}.
FT   STRAND      150    156       {ECO:0000244|PDB:1KQN}.
FT   HELIX       157    162       {ECO:0000244|PDB:1KQN}.
FT   TURN        166    168       {ECO:0000244|PDB:1KQN}.
FT   HELIX       171    180       {ECO:0000244|PDB:1KQN}.
FT   STRAND      183    188       {ECO:0000244|PDB:1KQN}.
FT   HELIX       190    198       {ECO:0000244|PDB:1KQN}.
FT   HELIX       201    205       {ECO:0000244|PDB:1KQN}.
FT   HELIX       206    209       {ECO:0000244|PDB:1KQN}.
FT   STRAND      210    214       {ECO:0000244|PDB:1KQN}.
FT   STRAND      217    219       {ECO:0000244|PDB:1KR2}.
FT   HELIX       223    231       {ECO:0000244|PDB:1KQN}.
FT   HELIX       242    251       {ECO:0000244|PDB:1KQN}.
FT   HELIX       256    259       {ECO:0000244|PDB:1KQN}.
FT   TURN        260    264       {ECO:0000244|PDB:1KQN}.
FT   HELIX       268    274       {ECO:0000244|PDB:1KQN}.
SQ   SEQUENCE   279 AA;  31932 MW;  740DE872CD9C22E7 CRC64;
     MENSEKTEVV LLACGSFNPI TNMHLRLFEL AKDYMNGTGR YTVVKGIISP VGDAYKKKGL
     IPAYHRVIMA ELATKNSKWV EVDTWESLQK EWKETLKVLR HHQEKLEASD CDHQQNSPTL
     ERPGRKRKWT ETQDSSQKKS LEPKTKAVPK VKLLCGADLL ESFAVPNLWK SEDITQIVAN
     YGLICVTRAG NDAQKFIYES DVLWKHRSNI HVVNEWIAND ISSTKIRRAL RRGQSIRYLV
     PDLVQEYIEK HNLYSSESED RNAGVILAPL QRNTAEAKT
//
